

ANTEOTECH EXPANDS IN JAPAN WITH APPOINTMENT OF LIFE SCIENCES DISTRIBUTOR

BRISBANE, AUSTRALIA, 28 May 2026: AnteoTech Ltd (ASX: ADO) ('AnteoTech' or 'the Company'), a supplier of advanced material solutions to the battery and life sciences markets, is pleased to announce:

Key Points:

- **Cosmo Bio Co., Ltd ('Cosmo Bio')**, a Tokyo Stock Exchange listed Japanese life sciences distributor, has been appointed to supply AnteoBind™ and related products in Japan, effective immediately.
- **Cosmo Bio works with more than 600 suppliers and has a well-established domestic distribution model servicing universities, public research institutes, and life sciences companies throughout Japan.**
- **AnteoTech's existing Japanese AnteoBind™ customer base includes the Japanese Red Cross Society and Chugai Pharmaceutical, a subsidiary of Roche. AnteoTech is seeking to build on these sales through this appointment.**
- **AnteoTech is progressing work on the diversification of its product portfolio to include Enzyme-Linked Immunosorbent Assays ('ELISA') and Chemiluminescence Immunoassays ('CLIA') products utilising AnteoBind NXT™ to activate surfaces and particles and deliver high-performing, lower-cost products into the market. With Japan under consideration as an initial pilot market, as outlined in the Company's March 2026 Quarterly Activities Report and recent market announcements.**
- **The Japanese In Vitro Diagnostics ('IVD') market is forecast to grow from ~US\$7.6 billion in 2026 to US\$9.5 billion by 2031¹.**
- **The Japanese ELISA and CLIA immunoassay markets within this broader IVD market generated ~US\$1.5 billion in sales revenue in 2024 and is forecast to reach ~US\$1.9 billion by 2030².**
- **This appointment supports the commercial expansion strategy of AnteoTech's Life Sciences business and establishes a non-exclusive sales channel for AnteoBind™ products in Japan, better servicing existing customers and facilitating broader market engagement and sales growth.**

Merrill Gray, Managing Director & Chief Executive Officer of AnteoTech, commented:

"The appointment of Cosmo Bio significantly expands AnteoTech's commercial presence in Japan through a highly regarded and well-established life sciences distribution partner."

"Cosmo Bio's extensive market reach, based on its large network, along with its technical engagement processes, capabilities and long-standing track record provide AnteoTech with an attractive channel to further expand AnteoBind™ sales in this important immunoassay market."

¹ <https://www.mordorintelligence.com/industry-reports/japan-in-vitro-diagnostics-market>

² <https://www.grandviewresearch.com/horizon/outlook/immunoassay-market/japan>

“This appointment supports AnteoTech’s strategy of building a scalable international distribution network, opening multiple channels for AnteoBind™ product sales including the Company’s ELISA and CLIA products currently in development. We look forward to providing updates here soon.”

Background

Cosmo Bio operates across the import, export, manufacture, marketing, sales and support of life sciences products, including reagents, kits, instruments and software³.

Under the distribution arrangement, Cosmo Bio will market and supply AnteoBind™ and related products into Japan for use in bioconjugation workflows within the IVD market, including to research institutes and organisations developing and utilising immunoassays.

Through its well-established domestic distribution network, Cosmo Bio provides AnteoTech with a highly scalable pathway to expand life sciences product sales across Japan.

This appointment provides AnteoTech with an established in-market commercial channel into one of Asia’s most advanced diagnostics and immunoassay markets, supporting the Company’s broader Life Sciences commercialisation strategy and future CLIA and ELISA market entry plans.

The agreement is non-exclusive and for an initial term of three years. There are no minimum purchase obligations and other terms of the agreement are confidential.

The Japanese market is strategically important given its advanced healthcare infrastructure, sophisticated diagnostics sector and strong adoption of high-performance immunoassay technologies. Customer engagement activities and product promotion through Cosmo Bio’s distribution network will commence immediately.

Japanese IVD Market Overview

Japan’s immunoassay market generated approximately **US\$1.5 billion** in revenue in 2024 and is forecast to grow to approximately **US\$1.9 billion by 2030**, representing a compound annual growth rate (“CAGR”) of 4.4% between 2025 and 2030².

The broader Japanese in-vitro diagnostics⁴ market is forecast to grow from approximately **US\$7.6 billion in 2026 to US\$9.5 billion by 2031**, representing a CAGR of 4.4%¹.

Japan’s ageing population and associated increase in chronic disease prevalence continue to drive demand for diagnostic testing, including immunoassay-based testing across infectious disease, oncology, cardiometabolic disease and inflammation¹.

Ongoing adoption of advanced diagnostic technologies, including highly sensitive assays, point-of-care formats, rapid testing and digital-health-enabled workflows, is supporting market growth across both immunoassays and the broader Japanese IVD market.

The rapid test segment is also forecast to expand as healthcare delivery increasingly shifts toward point-of-care testing and preventative medicine. This is creating a favourable environment for enabling technologies that improve assay performance and workflow usability, including AnteoBind™ and related products.

Japan remains a highly developed healthcare and research market with strong laboratory infrastructure, sophisticated end users focused on innovation and a sustained demand for high-quality reagents, kits and specialist assay components¹.

¹ <https://www.mordorintelligence.com/industry-reports/japan-in-vitro-diagnostics-market>

² <https://www.grandviewresearch.com/horizon/outlook/immunoassay-market/japan>

³ <https://www.cosmobio.com/en/company/overview/>

⁴ IVD includes immunoassays and molecular assays, AnteoBind is optimized only for immunoassays.

About Cosmo Bio Co., Ltd.

Cosmo Bio is a Tokyo-headquartered life sciences company listed on the Tokyo Stock Exchange Standard Market (Code 3386). Established in 1983, Cosmo Bio generated FY2025 sales revenue of approximately ¥10.04 billion Yen (A\$88.6 million).³

Cosmo Bio supplies life sciences research products and services across reagents, kits, instruments, software and drug discovery support, servicing universities, research institutes, biotechnology companies and broader healthcare markets across Japan.

The company operates an established domestic distribution network across Japan supported by regional dealer offices, supplier partnerships and technical customer support capabilities. Cosmo Bio also develops proprietary products and services in collaboration with external research institutes, supported by development and manufacturing activities at its Sapporo facility.

The Global IVD and Immunoassays markets context

Figure 1 below sets out the global IVD market value and its forecast growth along with global Immunoassays market overall value and forecast growth and the immunoassay sub sectors or market, by way of context.

Global IVD and Immunoassay Markets

All figures in US\$ Billions, as at 2024




Figure 1: Overview of global IVD and Immunoassay markets.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in ‘point of care’ and immunoassay diagnostic tests, enable faster, more reliable and accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.